ELMD vs SGHT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ELMD exhibits exceptional financial health, anchored by a strong Piotroski F-Score of 8/9 and a debt-free balance sheet (Debt/Equity 0.00). While the Graham Number suggests a defensive value of $11.28, the stock's growth profile—highlighted by a very low PEG ratio of 0.35 and consistent earnings beats—justifies its current premium. With an intrinsic value of $30.39 and an analyst target of $37.00, the stock is well-positioned for further upside. The combination of high gross margins (78.23%) and strong ROE (20.20%) indicates a highly efficient business model.
SGHT exhibits significant fundamental weakness, highlighted by a Piotroski F-Score of 3/9, placing it firmly in the 'Weak' health category. While the company maintains an exceptionally strong liquidity position (Current Ratio of 10.22) and impressive gross margins (86.17%), these are offset by deep negative profit margins and a lack of meaningful revenue growth (6.9% YoY). The bearish outlook is further solidified by aggressive insider selling across the C-suite and a 0/100 technical trend score, suggesting that the analyst target of $8.34 is disconnected from current internal sentiment and financial health.
Compare Another Pair
Related Comparisons
ELMD vs SGHT: Head-to-Head Comparison
This page compares Electromed, Inc. (ELMD) and Sight Sciences, Inc. (SGHT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.